



Joanne Langley Co-chair, President of WBE Canada



Dr. Langley is a pediatric infectious disease physician based at the IWK Health Centre and the Canadian Center for Vaccinology (CCfV) at Dalhousie University.

Dr. Langley is the Associate Director for Vaccine Evaluation Group at CCfV, and works with collaborators in academia, public health, industry, and non-governmental organizations to conduct phase 1 through 4 trials. She holds the CIHR-GSK Chair in Pediatric Vaccinology at Dalhousie University. She is an active investigator in the Canadian Immunization Research Network (CIRN) and is the lead investigator for its Clinical Trials Network (CTN).

Dr. Langley's work also focusses on vaccine policy and evidence-based decision making in immunization programs. She is a member of the COVID-19 Science Expert Panel for the Chief Science Advisor of Canada, and a former member of the Canadian Task Force on Preventive Health Care and Canada's National Advisory Committee on Immunization (Chair, 2007-2011), and serves as an advisor on several immunization decision-making expert groups.



J. Mark Lievonen **Co-chair, Principal, JML Advisory Services and former President,** **Sanofi Pasteur Limited**




Mr. Lievonen is the Principal of JML Advisory Services and the former President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi. He served as Chair of the Board of Directors of BIOTECCanada, Rx&D (now Innovative Medicines Canada), the Ontario Genomics Institute, the Markham Stouffville Hospital Foundation and the Centre for the Advancement of Health Innovation, as Vice-Chair of the Ontario Institute for Cancer Research, and as a member of the Board of Oncolytics Biotech, Acerus Pharmaceuticals, Quest PharmaTech, the Public Policy Forum and York University. Currently, he is a member of the Board of OncoQuest Pharmaceuticals Inc., Biome Grow Inc. and the Gairdner Foundation.

Mr. Lievonen was appointed to the Order of Canada, named a Chevalier de l'Ordre National duM rite by the Government of France, and inducted into the Canadian Healthcare Marketing Hall of Fame. He has received Lifetime Achievement Awards from Life Sciences Ontario and the Pharmaceutical Sciences Group, and the Canada Medal from The Chemical Institute of Canada.

Mr. Lievonen holds a BBA in accounting and a MBA in finance and marketing from the Schulich School of Business, and received a Honourary Doctor of Laws from York University. He is a Chartered Professional Accountant and was elected a Fellow of the Institute of Chartered Accountants of Ontario



Alan Bernstein **President and Chief Executive Officer, Canadian Institute for Advanced Research (CIFAR)**



Mr. Bernstein became CIFAR's President and Chief Executive Officer in May 2012. He served previously as executive director of the Global HIV Vaccine Enterprise in New York, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine.

From 2000 to 2007, Mr. Bernstein served as the inaugural president of the Canadian Institutes of Health Research (CIHR), Canada's federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada.

After receiving his PhD from the University of Toronto, and following postdoctoral work at the Imperial Cancer Research Fund in London, Mr. Bernstein joined the Ontario Cancer Institute in 1994. In 1985, he joined the Samuel Lunenfeld Research Institute, named Director of Research from 1994 to 2000.

Author of over 225 scientific publications, Mr. Bernstein has made landmark contributions to the study of stem cells, blood cell formation (hematopoiesis) and cancer. He chairs or is a member of advisory and review boards in Canada, the U.S., U.K., Italy and Australia.

Mr. Bernstein serves as co-chair of the Scientific Advisory Committee for Stand Up 2 Cancer Canada, is a member of the Sabin-Aspen Vaccine Science and Policy Group, and the Scientific Advisory Committee of the Bill and Melinda Gates Foundation.

Mr. Bernstein's contributions to science and science policy have been recognized with numerous awards and honorary degrees, including Officer of the Order of Canada, Order of Ontario, induction into the Canadian Medical Hall of Fame, and the 2017 Henry Friesen International Prize in Health Research.



Robert Brunham **Head, Vaccine Research Laboratory, British Columbia Centre for Disease Control; Professor of medicine, University of British**



Dr. Brunham is an emeritus professor of Medicine at the University of British

Columbia and Head of the Vaccine Research Laboratory at the UBC Centre for Disease Control. He is an internationally recognized leader in infectious disease prevention and control.

Using epidemiology, immunology and genomics he defined the population biology of important sexually transmitted pathogens including *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Haemophilus ducreyi*, *Treponema pallidum* and Human Immunodeficiency virus that improved control programs provincially, nationally and globally.

While Head of the British Columbia Centre for Disease Control he pioneered genomic approaches for emerging infectious diseases including SARS, pandemic Influenza, *Cryptococcus gattii* and tuberculosis which influenced how other disease control centres approach the problem of emerging infectious diseases.

His contribution to prevention and control of *Chlamydia trachomatis* and SARS has been widely recognized with honours and awards including the Order of British Columbia. He has over 300 peer-reviewed publications with an H-index of 83 and over 27,000 citations.



Michel De Wilde **Owner, MDWConsultant, llc; former Senior Vice President,** **Research & Development, Sanofi Pasteur**



Mr. De Wilde has a long career in vaccine research and development. He currently consults for the vaccine community.

From 2001 to June 2013, Mr. De Wilde was Senior Vice President, Research & Development, at Sanofi Pasteur.

While at Sanofi Pasteur, Mr. De Wilde drove the development and licensure by the FDA and other regulatory bodies of a number of products. Mr. De Wilde was also instrumental in driving the acquisition of and defining the integration model for two biotech companies: Acambis and VaxDesign.

Prior to joining Sanofi Pasteur, Mr. De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility to become Vice President, Research & Development. De Wilde has played a key role as a research scientist in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK's malaria vaccine.

Mr. De Wilde received his Ph.D. in Biochemistry in 1976, from the Free University of Brussels.



Bartha Maria Knoppers **Professor, Canada Research Chair in Law and Medicine; Director,** **Centre of Genomics and Policy, Faculty of Medicine, McGill** **University**



Mrs. Knoppers, PhD (Comparative Medical Law), is a Full Professor, Canada Research Chair in Law and Medicine and Director of the Centre of Genomics and Policy of the Faculty of Medicine at McGill University.

Mrs. Knoppers was the Chair of the Ethics and Governance Committee of the International Cancer Genome Consortium (2009-2017). She is currently Chair of the Ethics Advisory Panel of WADA (2015-), and was the Co-Chair of the Regulatory and Ethics Workstream of the Global Alliance for Genomics and Health (2013-2019). In 2015-2016, she was a member of the Drafting Group for the Recommendation of the OECD Council on Health Data Governance and gave the Galton Lecture in November 2017.

Mrs. Knoppers holds four Doctorates Honoris Causa and is a Fellow of the American Association for the Advancement of Science (AAAS), the Hastings Center (bioethics), the Canadian Academy Health Sciences (CAHS), and the Royal Society of Canada. She is also an Officer of the Order of Canada and of Quebec, and was awarded the 2019 Henry G. Friesen International Prize in Health Research, and was appointed to the International Commission on the Clinical Use of Human Germline Genome Editing



Gary Kobinger Professor and Director, Infectious Disease Research Centre, Université Laval



Mr. Kobinger obtained his Ph.D. from the University of Montreal in 1998 before completing a post-doctoral fellowship at the University of Pennsylvania. In March 2005, Mr. Kobinger was recruited by the Public Health Agency of Canada where he was from 2008 to 2016 the Chief of the Special Pathogens Biosafety Level 4 program at the National Microbiology Laboratory. He is now professor and the Director of the Infectious Disease Research Centre at the Université Laval and has an appointment of associate professor at the University of Manitoba and adjunct professor at the University of Pennsylvania.

Mr. Kobinger has been granted several awards including the Faculty Teaching Award from the University of Manitoba, the 2014 Gully award, the 2015 scientists of the year award from Radio Canada (CBC), the Order of Manitoba and the Meritorious Service Cross (civil division) of the Governor General of Canada in 2016, the Manning principal award in 2017 and the Governor General of Canada Innovation award in 2018. Mr. Kobinger has co-authored over 300 peer-reviewed scientific manuscripts, and has participated to many advisory boards to academic, national and international funding agencies, departments of national defenses, and the World Health Organization (WHO) concerning research on high-consequence pathogens and the development of new public health policies and recommendations. His work presently focusses on developing and testing new vaccine platforms and immune treatments against pathogens of high consequences to global public health.

In 2013-2020, 60 Minutes, National Geographic, BBC Horizon, NOVA, France 2, PBS, CBC, RC and others featured the leading work on successful treatment of Ebola infection that was developed by Mr. Kobinger and his team and the VSV-based Ebola vaccine to which he has also contributed to bringing to clinical trials



Christopher Procyshyn Chief Executive Officer and co-founder, Vanrx Pharmsystems



Mr. Procyshyn is the Chief Executive Officer of Vanrx Pharmsystems, a founder, and member of its Board of Directors. With over twenty-five years' experience in the pharmaceutical industry, Mr. Procyshyn has led teams in the development of complex injectable products in the fields of ophthalmology, oncology and reproductive health.

Globally experienced, he has negotiated the implementation of new technologies with many major regulatory agencies. Previously with QLT Inc., a pioneering Canadian biopharmaceutical company, he led the Manufacturing, Engineering and Process Sciences groups in the development of many advanced pharmaceutical processes and their implementation into manufacturing facilities in multiple countries.

Mr. Procyshyn is a microbiologist by education and training, and a graduate of the University of Saskatchewan.



Benjamin Rovinski Managing Director, Lumira Ventures



With over 30 years of investment, operational, managerial and research experience in the health care industry, Mr. Rovinski has helped build life sciences companies at all stages of development. Known both as a senior scientist and as an achievement-oriented executive, with demonstrated success in strategic planning, drug development, and operational management of global multifunctional teams, Mr. Rovinski has established a sound reputation built on his clarity of objectives, leadership, judgement and integrity. Mr. Rovinski's investment focus is primarily on North American mid- to late-stage private and public companies involved in drug discovery and development, biological and small-molecule therapeutics, drug delivery, specialty pharmaceuticals, genomics, proteomics and diagnostic devices.

With a proven track record of delivering results both as a senior scientist and a business executive, Mr. Rovinski has held several senior management positions in the biotechnology sector, including 13 years at Sanofi Pasteur (formerly Aventis Pasteur) where he was a senior scientist and director of molecular virology, with a particular focus in the areas of virology, vaccine development, recombinant protein production, and functional genomics. While at Aventis, Mr. Rovinski led global research and development programs in the areas of HIV/AIDS and therapeutic cancer vaccines, bringing several of them through to clinical stage.

Mr. Rovinski is fluent in English, French and Spanish. He has published over 25 scientific articles and reviews and is the recipient of 32 issued patents. Mr. Rovinski's current and past board roles and investment responsibilities include: Antiva Biosciences, Antios Therapeutics, Aurinia Pharmaceuticals (NASDAQ: AUPH), Bright Angel Therapeutics, G1 Therapeutics (Nasdaq: GTHX), KAI Pharmaceuticals (acquired by Amgen); Morphotek (acquired by Eisai), and Notch Therapeutics.

Mr. Rovinski also serves on the Board of Directors of Life Sciences Ontario, Ontario Genomics, and he volunteers for various personal career mentoring programs targeting young adult entrepreneurs.



Lorne Tyrrell **Founding Director, Li Ka Shing Institute of Virology; Distinguished** **University Professor, University of Alberta**



Dr. Lorne Tyrrell, OC, AOE, MD, PhD, FRCPC, FRSC, FCAHS holds the GSK Chair in Virology in the Department of Medical Microbiology and Immunology at the University of Alberta. He is also the Founding Director of the Li Ka Shing Institute of Virology. He has focussed his research since 1986 on viral hepatitis. His work on the development of antiviral therapy was supported by the Canadian Institutes of Health Research (CIHR) and Glaxo Canada. It resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection – lamivudine – in 1998. Today, lamivudine is licensed in over 200 countries worldwide for the treatment of HBV. He has also been involved in the establishment of a biotech company—KMT Hepatech Inc. based on the first non-primate animal model for HCV

in 2003. KMT Hepatech was sold to PhoenixBio in 2017.

Dr. Tyrrell was the Dean of the Faculty of Medicine and Dentistry from 1994-2004. Since leaving the deanship in 2004, Dr. Tyrrell has held a number of important board positions in health care in Alberta and Canada. These include the Chair of the Board of the Institute of Health Economics (2004-2018) and the Chair of the Board of the Health Quality Council of Alberta (2003-2012). He was the Chair of the Gairdner Foundation Board (2009-2019) and serves on the Research Advisory Council for the Canadian Institute for Advanced Research, was appointed to the Science Advisory Board to Health Canada, and chaired the Board of Alberta Precision Laboratories (2018-2019).

For his studies on viral hepatitis, Dr. Tyrrell has received numerous prestigious awards including the Gold Medal of the Canadian Liver Foundation (2000), the Alberta Order of Excellence (2000), Officer of the Order of Canada (2002), Fellow of the Royal Society (2004), FNG Starr Award of the Canadian Medical Association (2004), and the Principal Award of the Manning Foundation (2005). He was awarded the University Distinguished Professorship at the University of Alberta and was inducted into the Canadian Medical Hall of Fame in April 2011. In 2015, he was awarded the Killam Prize in Health Sciences.



Sylvia van drunen Littel-van den Hurk

Professor, Biochemistry, Microbiology & Immunology, College of Medicine, University of Saskatchewan; Program Manager, Viral Pathogenesis and Vaccine Development, VIDO-InterVac, University of Saskatchewan



Dr. Sylvia van den Hurk is Professor of Biochemistry, Microbiology & Immunology in the College of Medicine, University of Saskatchewan, Canada. She is also the Program Manager of the Viral Pathogenesis & Vaccine Development group in VIDO-InterVac. Dr. van den Hurk received her B.Sc. and MSc at the University of Wageningen in the Netherlands and a PhD at University of Saskatchewan. Her research interests are viral disease control and virus-host interactions, with focus on respiratory syncytial virus, parainfluenzavirus-3, bovine herpesvirus, and bovine viral diarrhea virus. Dr. van den Hurk developed several DNA and subunit vaccine candidates, one of them against respiratory syncytial virus, as well as a number of adjuvants.

Dr. van den Hurk has (co-) authored more than 225 peer-reviewed manuscripts, review articles, and book chapters, and holds/contributed to 12 patents. She has mentored over 60 students and post-doctoral fellows. Her research is/has been funded by international (Bill and Melinda Gates Foundation), national (Canadian Institutes for Health Research, Natural Sciences and Engineering Council) and provincial granting agencies. Dr. van den Hurk has served as reviewer on several national and international grant review panels. She is Associate Editor for the journal *Vaccine*, and is on the editorial board of the journal *npj Vaccines* (Nature Publishing).



André Veillette

Professor, Department of Medicine, Université de Montréal; Director, Molecular Oncology Research Unit, Montreal Clinical Research Institute (IRCM)



After completing his medical training in 1981 at the Université Laval, Dr. André Veillette did a residency in Internal Medicine at the Montreal General Hospital and basic research training in immunology at the National Cancer Institute in the United States. He joined the Faculty of Medicine at McGill University in September 1989 and, in 1999, relocated his laboratory to the Montréal Clinical Research Institute (IRCM) and the Université de Montréal.

Dr. Veillette's research contributions have been recognized at the national level. In 1992, he won the Young Investigator Award from Bio-Méga Boehringer-Ingelheim. Dr. Veillette subsequently received in 1994 the William E. Rawls Award of the National Cancer Institute of Canada. In 1999, he was awarded the Young Investigator Award "André Dupont" from the Club de Recherches Cliniques du Québec. In 2000, Dr. Veillette was the recipient of the Merck Frosst Prize. In 2007, he received the Leo-Pariseau Prize. Dr. Veillette was also awarded a Medical Research Council of Canada Scholarship and a Canadian Institutes of Health Research Scientist Award. In 2008, Dr. Veillette was elected Member of the Royal Society of Canada.

Dr. Veillette's accomplishments have also been acknowledged at the international level, participating in a number of Editorial Boards. As a reflection of his contribution to basic research, Dr. Veillette was elected a Member of the American Society for Clinical Investigation in 1995. Furthermore, in 2007, he was awarded an International Scholar Award from the Howard Hughes Medical Institute (HHMI).